Elsevier

Oral Oncology

Volume 68, May 2017, Pages 9-19
Oral Oncology

Review
Can gene editing and silencing technologies play a role in the treatment of head and neck cancer?

https://doi.org/10.1016/j.oraloncology.2017.02.016Get rights and content

Highlights

  • Gene silencing and editing technology is now routine in the laboratory.

  • Advanced bioinformatics of head and neck cancer is required.

  • Clinically useful delivery systems and target selection are critical barriers.

  • The PLAS, nano-patch & microneedle approaches could be potential delivery systems.

  • Targeting E6 & E7 could be an effective treatment strategy for HPV-positive HNSCC.

Abstract

Conventional treatment strategies have done little to improve the prognosis or disease-free survival in head and neck cancer (HNC) patients. Recent progress in our understanding of molecular aspects of head and neck squamous cell carcinoma (HNSCC) has provided insights into the potential use of molecular targeted therapies in combination with current treatment strategies. Here we review the current understanding of treatment modalities for both HPV-positive and HPV-negative HNSCCs with the potential to use gene editing and silencing technologies therapeutically. The development of sequence-specific RNA interference (RNAi) with its strong gene-specific silencing ability, high target specificity, greater potency and reduced side effects, has shown it to be a promising therapeutic candidate for treating cancers. CRISPR/Cas gene editing is the newest technology with the ability to delete, mutate or replace genes of interest and has great potential for treating HNSCCs. We also discuss the major challenge in using these approaches in HNSCC; that being the choice of target and the ability to deliver the payload. Finally, we highlight the potential combination of RNAi or CRIPSR/Cas with current treatment strategies and outline the possible path to the clinic.

Introduction

Head and neck cancer (HNC) is a major health problem and a leading cause of morbidity and mortality worldwide. It is regarded as the sixth most common cancer in the world. More than 90% of these malignancies are head and neck squamous cell carcinoma (HNSCC), which mostly comprise of oral squamous cell carcinoma (OSCC), oropharyngeal squamous cell carcinoma (OPSCC) and Laryngeal squamous cell carcinoma (LSCC) [1], [2]. Tobacco use in different forms (including smoking and smokeless tobacco), areca nut and alcohol consumption are the most common risk factors for the development of HNSCC [3], [4]. However, there is now irrefutable evidence of strong association of human papillomavirus (HPV) with HNSCC, especially for OPSCC in younger adult males [5], [6]. Current treatment of HNSCC still involves conventional surgery, chemotherapy, and radiotherapy, or a combination of these. Radical surgical excision followed by radiotherapy, with or without adjunct chemotherapy, is now commonplace. Due to the complex and delicate anatomical structure of the face and neck, the extent of surgery may be limited, as wide excision results in visible and functional facial deformities: radiotherapy and chemotherapy have low specificity for individual neoplasms and have toxicities affecting the whole body [7]. HNSCC show a wide arrangement of genetic aberrations, increasing with tumour progression and these contribute to a therapeutic failure with conventional therapies [8]. Although in Western countries the average 5-year survival rate for HNSCC patients is now ∼60%, one-third of patients develop local or/and regional metastases which reduce survival to less than a year [9], [10]. It is clear that there is a need for the development of new treatment approaches, which would better preserve the patient’s physical functions and their quality of life. Targeted molecular therapeutics are promising alternatives for treating cancer patients more efficiently and with limited side effects. One approach is blocking or silencing the expression of a specific gene (or genes) that is vital for continued growth of the neoplasm. Gene silencing or editing, via RNA interference (RNAi) and clustered, regularly interspaced, short palindromic repeats – associated with cellular apoptotic susceptibility protein (CRISPR/Cas) respectively, offer new possibilities for HNSCC treatment. The ability of RNAi to suppress the expression of target genes with high efficiency and specificity is well known. CRIPSR/Cas is a more recent discovery that allows the in situ manipulation of target genes but its clinical efficacy is yet to be proven [11]. The issue is which gene does one target and how will the therapy be delivered? Here we discuss gene editing and silencing mechanisms, potential candidate genes and review the various delivery technologies that could be used for HNSCC treatment. We highlight the potential path from bench to bedside for the improved treatment of HNSCC.

Section snippets

Gene editing and silencing

Both RNAi and CRISPR/Cas are programmable systems that allow one to specifically target a mRNA or gene, respectively. By providing each with sequence-specific RNA templates to their target, one is able to precisely change the output of that gene. RNAi achieves this via small non-coding RNAs such as short interfering RNA (siRNA), micro RNA (miRNA) or short hairpin RNAs (shRNAs) [12], [13], [14] and takes advantage of a normal cell regulatory system built into every eukaryotic cell.

CRISPR/Cas (gene editing) in cancer treatment

The recent advent of genome editing technologies based on programmable nuclease have improve the ability to delete or modify specific nucleic acid sequences in the genome of cells or in the animal models that aided us to explore the role of particular genes in the cancer progression and therapeutic responses. These nucleases include; the ZFNs, TALENs and most recently discovered the CRISPR associated nuclease Cas9 protein that enabled site-specific genome editing with the potential of using as

Currently available delivery technologies

The ultimate success of these therapies relies on the adequate delivery of the siRNA or CRISPR/Cas system into the cell. While siRNA delivery is either via synthetic RNA or a DNA plasmid, CRIPSR/Cas can be delivered in a variety of forms including guide RNA (gRNA)/DNA (expressing Cas protein), as gRNA/mRNA for Cas, or RNA/Cas protein. Nevertheless, the challenges for delivery are the same for both systems as delivery of RNA or DNA encounters a range of barriers that must be overcome. These

Target selection

The treatment-related toxicities, complications and recurrence rates, especially in advanced disease stages, with current conventional therapies have necessitated the focus on molecular targeted therapy. Currently, we are using the same treatment strategies to treat HPV-positive and HPV-negative HNSCC but they are clearly two different types of malignancy. Moreover, the key drivers of cancer formation and maintenance are also different in each type (and likely there are many more sub-types

Delivery in the HNSCC setting

Here we will consider delivery in the context of siRNA but as mentioned above, the challenges apply equally to CRISPR/Cas. In the HNSCC setting, the ability to deliver siRNA in the tumour microenvironment for effective gene silencing is a critical issue. Here we suggest several approaches that offer a potential way forward (Fig. 4). The preferred approach would be localised delivery directly to the tumour site as this avoids a number of issues found with systemic delivery, such as poor

Challenges and gaps

Both the RNAi and CRISPR/Cas system have the potential to play a major role in HNSCC treatment. RNAi-based therapies for HNSCC are still at the preclinical stage but show considerable promise. The CRISPR/Cas approach has the added advantages of being able to repress multiple target genes simultaneously and to permanently change genetic codes at genome level, but it is still too early to predict their clinical use. To date, only 10 early-phase clinical trials (phase I or phase I/II) of siRNA and

Conclusion

Even with the rapid progress of science and technology and advancement of treatment strategies, head and neck cancer remains a significant cause of morbidity and mortality worldwide. While RNAi therapies against cancer have not yet been tested in human trials, they have been shown to reduce the expression of targeted proteins with very limited side effects, both efficiently and specifically. This suggests their potential for treating cancers in humans efficiently. We believe that gene silencing

Conflict of interest

None declared.

Acknowledgements

MHS is funded by Griffith University, Australia. NAJM has received funding from the Cancer Council of Queensland and the National Health and Medical Research Council of Australia.

References (117)

  • J.A. Bonner et al.

    Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

    Lancet Oncol

    (2010)
  • H. Dudek et al.

    Knockdown of beta-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo

    Mol Ther

    (2014)
  • P.H. Maxwell et al.

    Activation of the HIF pathway in cancer

    Curr Opin Genet Dev

    (2001)
  • W.H. Chen et al.

    Nanoparticle delivery of HIF1alpha siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer

    Cancer Lett

    (2015)
  • A.R. Giuliano et al.

    Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

    Vaccine

    (2008)
  • P.L. Stern et al.

    Therapy of human papillomavirus-related disease

    Vaccine

    (2012)
  • E.M. Kennedy et al.

    Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease

    Virology

    (2015)
  • S. Zhen et al.

    In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9

    Biochem Biophys Res Commun

    (2014)
  • S.Y. Wu et al.

    Vaginal delivery of siRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system

    J Control Release

    (2011)
  • Y. Zhang et al.

    Engineering mucosal RNA interference in vivo

    Mol Ther

    (2006)
  • R.H. Chong et al.

    Gene silencing following siRNA delivery to skin via coated steel microneedles: in vitro and in vivo proof-of-concept

    J Control Release

    (2013)
  • O. Haigh et al.

    CXCL1 gene silencing in skin using liposome-encapsulated siRNA delivered by microprojection array

    J Control Release

    (2014)
  • X. Chen et al.

    Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization

    J Control Release

    (2011)
  • P. Barata et al.

    RNA-targeted therapeutics in cancer clinical trials: current status and future directions

    Cancer Treat Rev

    (2016)
  • H. Xu et al.

    Amphiphilic poly(amino acid) based micelles applied to drug delivery: the in vitro and in vivo challenges and the corresponding potential strategies

    J Control Release

    (2015)
  • L. Messager et al.

    Novel aspects of encapsulation and delivery using polymersomes

    Curr Opin Pharmacol

    (2014)
  • Z. Gao et al.

    Nanotechnology applied to overcome tumor drug resistance

    J Control Release

    (2012)
  • C.R. Leemans et al.

    The molecular biology of head and neck cancer

    Nat Rev Cancer

    (2011)
  • M. Hashibe et al.

    Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium

    J Natl Cancer Inst

    (2007)
  • N.W. Johnson et al.

    Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and aetiology

    Periodontol

    (2000)
  • G. D'Souza et al.

    Case-control study of human papillomavirus and oropharyngeal cancer

    N Engl J Med

    (2007)
  • T. Ramqvist et al.

    An epidemic of oropharyngeal squamous cell carcinoma (OSCC) due to human papillomavirus (HPV) infection and aspects of treatment and prevention

    Anticancer Res

    (2011)
  • B.A. Murphy et al.

    Systemic and global toxicities of head and neck treatment

    Expert Rev Anticancer Ther

    (2007)
  • Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature...
  • A. Forastiere et al.

    Head and neck cancer

    N Engl J Med

    (2001)
  • G.J. Schwartz et al.

    Salvage treatment for recurrent squamous cell carcinoma of the oral cavity

    Head Neck

    (2000)
  • J.D. Sander et al.

    CRISPR-Cas systems for editing, regulating and targeting genomes

    Nat Biotechnol

    (2014)
  • J.S. Mattick

    Non-coding RNAs: the architects of eukaryotic complexity

    EMBO Rep

    (2001)
  • Mattick JS, Makunin IV. Non-coding RNA. Hum Mol Genet 2006;15 Spec No...
  • P. Carninci et al.

    The transcriptional landscape of the mammalian genome

    Science

    (2005)
  • S.M. Elbashir et al.

    RNA interference is mediated by 21- and 22-nucleotide RNAs

    Genes Dev

    (2001)
  • R.F. Ketting et al.

    Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans

    Genes Dev

    (2001)
  • M.A. Matzke et al.

    RNAi-mediated pathways in the nucleus

    Nat Rev Genet

    (2005)
  • R. Yi et al.

    Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs

    Genes Dev

    (2003)
  • H. Kawasaki et al.

    Induction of DNA methylation and gene silencing by short interfering RNAs in human cells

    Nature

    (2004)
  • K.V. Morris et al.

    Small interfering RNA-induced transcriptional gene silencing in human cells

    Science

    (2004)
  • S.M. Hammond et al.

    Argonaute2, a link between genetic and biochemical analyses of RNAi

    Science

    (2001)
  • F. Takeshita et al.

    Therapeutic potential of RNA interference against cancer

    Cancer Sci

    (2006)
  • I. Grissa et al.

    The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats

    BMC Bioinformatics

    (2007)
  • K.S. Makarova et al.

    A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action

    Biol Direct

    (2006)
  • Cited by (7)

    • Oral submucous fibrosis associated oral squamous cell carcinoma: A case report with review of literature

      2022, Oral and Maxillofacial Surgery Cases
      Citation Excerpt :

      The treatment for OSCC is mostly surgery followed by radiation therapy and chemotherapy. However, recently, there have been advancement in the treatment of OSCC with the development of modern technologies [13]. The management guidelines of OSCC mostly follow curative intent unless the tumor stage or the patient's condition demands otherwise [14].

    • Novel therapies in the management of oral cancer: An update

      2020, Disease-a-Month
      Citation Excerpt :

      Nanoparticle based systems are specific and more efficient since these are taken up by the cells and are released in cell interiors in a sustained manner. Delivery systems include biodegradable PLAS system, muco-adhesive hydrogels, nanopatches, micro-needle array devices, which are used in oral and pharyngeal cancers.27 Nucleic acid based RNAi therapy has some draw backs like gene silencing may target genes are that are not supposed to be silenced.

    • Liquid biopsy: miRNA as a potential biomarker in oral cancer

      2019, Cancer Epidemiology
      Citation Excerpt :

      Exosomal purification and isolation of RNA from body fluids and normalization with an exogenous control are important to reduce variation due to RNA degradation. A therapeutic role for miRNAs requires further work on a suitable in-vivo delivery device or mechanism [77,78]. This work was supported by the CSIR extramural (Grant no 27(0306)/14//EMR-II) to RC, JR and KC and ISI intramural funding to RC.

    View all citing articles on Scopus
    View full text